Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression

Zhong, Mingtian; Wang, Xiang; Xiao, Jing; Yi, Jinyao; Zhu, Xueling; Jian, Lin; Wang, Wei; Yao, Shuqiao

doi:10.1016/j.biopsycho.2011.08.007

Cited by 140 publications

(95 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of fMRI studies have reported amygdala hyper-reactivity in response to negative emotional faces in MDD overall relative to controls under both supraliminal (Peluso et al, 2009;Surguladze et al, 2005;Fu et al, 2004;Zhong et al, 2011) and subliminal (Sheline et al, 2001;Victor et al, 2010;Stuhrmann et al, 2012;Suslow et al, 2010) (for meta-analysis see the study by Hamilton et al (2012); for review see the studies by Browning et al (2010);Jaworska et al (2014)). These studies have typically reported on medicated patients, who by virtue of still meeting criteria for the disorder while on medication are likely non-responders.…”

Section: Discussionmentioning

confidence: 99%

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

Williams

Korgaonkar

Song

et al. 2015

Neuropsychopharmacol

170

125

View full text Add to dashboard Cite

Although the cost of poor treatment outcomes of depression is staggering, we do not yet have clinically useful methods for selecting the most effective antidepressant for each depressed person. Emotional brain activation is altered in major depressive disorder (MDD) and implicated in treatment response. Identifying which aspects of emotional brain activation are predictive of general and specific responses to antidepressants may help clinicians and patients when making treatment decisions. We examined whether amygdala activation probed by emotion stimuli is a general or differential predictor of response to three commonly prescribed antidepressants, using functional magnetic resonance imaging (fMRI). A test-retest design was used to assess patients with MDD in an academic setting as part of the International Study to Predict Optimized Treatment in Depression. A total of 80 MDD outpatients were scanned prior to treatment and 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and sertraline and the serotonin-norepinephrine reuptake inhibitor, venlafaxine-extended release (XR). A total of 34 matched controls were scanned at the same timepoints. We quantified the blood oxygen level-dependent signal of the amygdala during subliminal and supraliminal viewing of facial expressions of emotion. Response to treatment was defined by ⩾ 50% symptom improvement on the 17-item Hamilton Depression Rating Scale. Pre-treatment amygdala hypo-reactivity to subliminal happy and threat was a general predictor of treatment response, regardless of medication type (Cohen's d effect size 0.63 to 0.77; classification accuracy, 75%). Responders showed hypo-reactivity compared to controls at baseline, and an increase toward 'normalization' post-treatment. Pre-treatment amygdala reactivity to subliminal sadness was a differential moderator of non-response to venlafaxine-XR (Cohen's d effect size 1.5; classification accuracy, 81%). Non-responders to venlafaxine-XR showed pre-treatment hyperreactivity, which progressed to hypo-reactivity rather than normalization post-treatment, and hypo-reactivity post-treatment was abnormal compared to controls. Impaired amygdala activation has not previously been highlighted in the general vs differential prediction of antidepressant outcomes. Amygdala hypo-reactivity to emotions signaling reward and threat predicts the general capacity to respond to antidepressants. Amygdala hyper-reactivity to sad emotion is involved in a specific non-response to a serotonin-norepinephrine reuptake inhibitor. The findings suggest amygdala probes may help inform the personal selection of antidepressant treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

Williams

Korgaonkar

Song

et al. 2015

Neuropsychopharmacol

170

125

View full text Add to dashboard Cite

show abstract

“…Moreover, these alterations are also related to the treatment response, particularly in patients with treatment-refractory depression [32][33][34][35][36]. Simultaneously, according to some previous studies, structural and functional alterations in the temporal lobe and sgACC overlap in patients with major depression and schizophrenia [8,9,10,37]. Our findings converged with the previous findings to support the hypothesis that the sgACC is a pathological centre in patients with MDD and the hypothesis that the sgACC is a common pathological feature in patients with schizophrenia and depression [32][33][34][35][36][37].…”

Section: Discussionmentioning

confidence: 84%

“…These studies have acquired important and useful information that has improved our understanding of the biological basis of schizophrenia and have provided many indices to aid psychiatrists in improving the rates of accurate diagnoses and treatment efficacies [9][10][11][12][13][14][15][16][17]. However, most of these previous studies have focused on exploring the common brain features shared by patients with schizophrenia and depression, these previous studies have provided evidence that structural or functional impairments in some brain regions in patients with schizophrenia overlap with impairments observed in patients with MDD to some extent, The temporal lobe and anterior cingulate are the main affected regions [7,[18][19][20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: Introductionmentioning

confidence: 99%

Depressive symptom in the first-episode schizophrenic patients is related to the reduction of grey matter volume in the subgenual anterior cingulate cortex - a pilot study

Xu¹,

He²,

Chen³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Approximately 25-75% of patients with schizophrenia also present major depressive systems. Investigations into the pathological features associated with depressive symptoms in patients with schizophrenia would provide important information for the development of treatments for depressive symptoms in patients with schizophrenia. In present study, we enrolled 17 first-episode schizophrenic patients with depressive symptoms and 17 well-matched first-episode schizophrenic patients without depressive symptoms and compared differences in their grey mater volume (GMV) using voxel-based morphometry (VBM). We observed significantly decreased GMV in the subgenual anterior cingulate cortex (sgACC) in the first episode schizophrenic patients with depressive symptoms compared to the first episode schizophrenic patients without depressive symptoms. However, we did not observe a correlation between the severity of the decreased GMV and the severity of depressive symptoms. Although convincing evidence supporting this postulation is lacking and requires further study for confirmation, to some extent, our findings provide indirect evidence for the suggestion that the reduction of the GMV in the sgACC may play a key role in the depressive symptoms in the first episode schizophrenic patients.

show abstract

“…These results suggest that patients with reduced amygdala-dlPFC interaction have a longer and more severe course of disease (Dannlowski et al, 2009). A recent fMRI study showed that both medication-free MDD patients (n=29) and never-depressed subjects with cognitive vulnerability to depression (n=26) displayed similar responses to emotional stimuli, with significantly lower activity in the dlPFC and significantly greater activity in the amygdala than healthy control subjects (n=31) (Zhong et al, 2011).…”

Section: Traumatic Experiences Disrupt Amygdala-prefrontal Connectivitymentioning

confidence: 90%

Traumatic Experiences Disrupt Amygdala – Prefrontal Connectivity

Oh¹

2012

The Amygdala - A Discrete Multitasking Manager

View full text Add to dashboard Cite

Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression

Cited by 140 publications

References 64 publications

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

Depressive symptom in the first-episode schizophrenic patients is related to the reduction of grey matter volume in the subgenual anterior cingulate cortex - a pilot study

Traumatic Experiences Disrupt Amygdala – Prefrontal Connectivity

Contact Info

Product

Resources

About